Prosite

Prosit Sole Biotechnology is a clinical-stage biotechnology company dedicated to the discovery and development of novel protein therapeutics for severe rare diseases and life-threatening viral infections. The company leverages its proprietary P-POP (Prositsole Protein Optimize Platform) to engineer chimeric biologics designed for enhanced efficacy and favorable safety profiles. Its lead candidate, PSP001, is a first-in-class PEGylated Interferon-lambda chimera currently undergoing Phase 1 clinical evaluation for indications including Fetal and Neonatal Alloimmune Thrombocytopenia (FNAIT). Prosit Sole maintains a dual presence in the United States and China, integrating capabilities in protein design, drug screening, and high-quality manufacturing.